This CME underscores sacubitril/valsartan as a paradigm shift that bridges prevention and treatment in the cardiovascular continuum, offering broad benefits across diverse patient pop... See more
This CME reviews the 2025 ESC/EAS LDL-C management guidelines, highlighting optimized treatment sequencing and combination therapy with bempedoic acid to improve ASCVD risk reduction.... See more
This lecture reviews the expanding role of GLP-1 receptor agonists, especially semaglutide, in cardiometabolic disease, highlighting evidence for cardiovascular, renal, and metabolic ... See more